Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624.
The accumulation of triacylglycerol in adipocytes causes obesity. Diacylglycerol acyltransferase (DGAT) catalyzes the final reaction of triacylglycerol synthesis. Two isozymes, DGAT1 and DGAT2, have been reported, and DGAT1 is considered a potential therapeutic target of inhibition for obesity control. Patent WO2009126624 proposes 69 new triazolopyridine compounds as DGAT1 inhibitors by Bristol-Myers Squibb. The inhibitory activity of these triazolopyridine compounds was assessed in an enzyme assay using microsomal fractions prepared from human DGAT1-expressing insect cells. Among them, four derivatives inhibited DGAT activity with IC(50) values of < 0.1 microM.